BACKGROUND Intraocular pressure (IOP) is the major known risk factor in glaucoma and the primer mover of the functional damage in glaucomatous patients but it is not a unique determinant of glaucomatous damage. Clinical assessment of glaucoma patients may not be a true reflection of overall IOP control. Evaluation of the effect of glaucoma medication is restricted by measurement of IOP as a dyn...

INTRODUCTION The purpose of this study was to document the efficacy and tolerability of the new fixed-combination (FC) brinzolamide 1%/timolol 0.5% as used in daily practice throughout Germany. METHODS An open-label, multicenter, observational study of patients was performed that evaluated the transition from prior medication to brinzolamide/timolol FC for the reduction of intraocular pressur...

PURPOSE To evaluate the effect of topical antiglaucoma medications on the lacrimal drainage system. METHODS In a prospective controlled blind observational case series, 627 eyes of 384 patients (219 males, 165 females) were screened. Data recording (demographics and history taking), allocation in case (on topical antiglaucoma medications) and control (no glaucoma) groups, and examinations (ey...

This study was aimed to evaluate the prophylactic anti-glaucoma effect of topical 5% betaxolol (BTX) and 2% dorzolamide (DRZ) on second eye in dogs with unilateral primary angle closure glaucoma (PACG). Medical records 60 PACG who received eyedrops eye, from 2016 2021, were reviewed. The duration effects BTX only DRZ after failure calculated. maintained 28/60 (46.7%) eyes until last visit obser...

fir-pose: Dorzolamide @ORE) is a topical carbonic anhydrase (CA) inhibitor that is approved for treatment of open-angle glauccma and ocular hypertension. DORE exerts its effects directly in the eye at substantially lower doses and therefore with less systemic exposure than oral CA inhibitors To evaluate DORZ's potential for systemic CA inhibition, maximum systemic exposure was simulated through...